Sandoz Talks US Biosimilars And Misinformation
Q&A With Hillel Cohen, Sandoz' Executive Director, Scientific Affairs
Executive Summary
Increasing access and use of lower cost biosimilars by combatting disparagement and misinformation is more important now than ever, as the COVID-19 pandemic cripples economies across the globe, argues Sandoz’ executive director for scientific affairs, Hillel Cohen.
You may also be interested in...
Biosimilar Interchangeability: A Blessing Or A Curse?
Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.
Biosimilar Interchangeability: A Blessing Or A Curse?
Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.
Misinformation Contributing To Slower Biosimilar Uptake, Execs Claim
Dispelling myths around biosimilar efficacy and safety may be crucial to driving uptake of biosimilars, executives from Sandoz and Boehringer Ingelheim have argued in an opinion piece in the journal, BioDrugs, as they asserted it was the “responsibility of all stakeholders to challenge biosimilar disparagement and misinformation when encountered.”